Department of Pharmacology, Nihon University School of Dentistry at Matsudo, Sakaecho-Nishi, Matsudo, Chiba, Japan.
Nihon University Graduate School of Dentistry at Matsudo, Oral Molecular Pharmacology, Sakaecho-Nishi, Matsudo, Chiba, Japan.
PLoS One. 2024 Jun 10;19(6):e0292830. doi: 10.1371/journal.pone.0292830. eCollection 2024.
Lipopolysaccharide (LPS), a component of the Gram-negative bacterial cell wall, activates Toll-like receptors (TLRs). Porphyromonas gingivalis (Pg) may be involved in the progression of periodontal disease. Mice exposed to a novel environment show hyperlocomotion that is inhibited by systemic administration of LPS derived from Escherichia coli (Ec-LPS). However, whether Pg-LPS influences novelty-induced locomotion is unknown. Accordingly, we carried out an open field test to analyse the effects of Pg-LPS. For comparison, effects of Ec-LPS were also studied. We additionally investigated the influence of systemic administration of Pg-LPS or Ec-LPS on IL-6, TNF-alpha, and IL-10 levels in blood, as they could be involved in the changes in locomotion. The TLR4 receptor antagonist TAK-242 was used to study the involvement of TLR4. Since Pg-LPS may block TLR4 in vitro, we analysed the effects of Pg-LPS on Ec-LPS-induced changes in behavioural and biochemical parameters. Male ddY mice were used. Pg- or Ec-LPS and TAK-242 were administered intraperitoneally. Ec-LPS (840 μg/kg), but not Pg-LPS (100, 500 and 840 μg/kg), inhibited novelty-induced locomotion, which was antagonized by TAK-242 (3.0 mg/kg). Ec-LPS (840 μg/kg) increased blood levels of IL-6 and IL-10, which were antagonized by TAK-242 (3.0 mg/kg). However, TAK-242 did not inhibit Ec-LPS-induced increases in TNF-alpha levels in blood. Pg-LPS (100, 500, and 840 μg/kg) did not alter blood IL-6, TNF-alpha, or IL-10 levels. The Ec-LPS-induced increase in blood IL-10, but not IL-6 and TNF-alpha, levels was inhibited by Pg-LPS (500 μg/kg). These results suggest that TLR4 stimulation mediates the inhibition of novel environment-induced locomotion in mice following systemic administration of Ec-LPS, while also increasing blood IL-6 and IL-10 levels. In contrast, Pg-LPS did not exhibit these effects. The present study also provides in vivo evidence that Pg-LPS can inhibit TLR4-mediated increases in blood levels of IL-10, a cytokine thought to prevent the development of periodontal disease.
脂多糖(LPS)是革兰氏阴性细菌细胞壁的组成部分,能激活 Toll 样受体(TLR)。牙龈卟啉单胞菌(Pg)可能参与牙周病的进展。暴露于新环境中的小鼠表现出过度活跃,这种过度活跃可被源自大肠杆菌(Ec-LPS)的全身 LPS 给药抑制。然而,Pg-LPS 是否会影响新奇诱导的运动尚不清楚。因此,我们进行了一个开放场测试来分析 Pg-LPS 的作用。为了比较,还研究了 Ec-LPS 的作用。我们还研究了全身给予 Pg-LPS 或 Ec-LPS 对血液中 IL-6、TNF-α 和 IL-10 水平的影响,因为它们可能与运动变化有关。使用 TLR4 受体拮抗剂 TAK-242 来研究 TLR4 的参与情况。由于 Pg-LPS 在体外可能会阻断 TLR4,我们分析了 Pg-LPS 对 Ec-LPS 诱导的行为和生化参数变化的影响。使用雄性 ddY 小鼠。腹腔内给予 Pg-LPS 或 Ec-LPS 和 TAK-242。Ec-LPS(840μg/kg),但不是 Pg-LPS(100、500 和 840μg/kg),抑制新奇诱导的运动,这种抑制作用可被 TAK-242(3.0mg/kg)拮抗。Ec-LPS(840μg/kg)增加血液中 IL-6 和 IL-10 的水平,这些水平可被 TAK-242(3.0mg/kg)拮抗。然而,TAK-242 并没有抑制 Ec-LPS 诱导的血液中 TNF-α水平的升高。Pg-LPS(100、500 和 840μg/kg)并没有改变血液中 IL-6、TNF-α或 IL-10 的水平。Pg-LPS(500μg/kg)抑制了 Ec-LPS 诱导的血液中 IL-10 水平的升高,但没有抑制 IL-6 和 TNF-α水平的升高。这些结果表明,TLR4 刺激介导了全身给予 Ec-LPS 后小鼠新奇环境诱导的运动抑制,同时也增加了血液中 IL-6 和 IL-10 的水平。相比之下,Pg-LPS 没有表现出这些作用。本研究还提供了体内证据,表明 Pg-LPS 可以抑制 TLR4 介导的血液中 IL-10 水平的升高,而 IL-10 被认为可以预防牙周病的发生。